Rigel Pharmaceuticals Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Rigel Pharmaceuticals Inc's ROA in the second quarter of 2026?
Rigel Pharmaceuticals Inc achieved a return on average assets (ROA) of 72.27 % in its second quarter of 2026, this is above RIGL's average return on assets of -28.54%.
Rigel Pharmaceuticals Inc assets over the 12 months ending in its second quarter of 2026 are valued at $445 million

ROA fell compared to the first quarter of 2026, despite the net income growth of 99.79% from the first quarter of 2026.

However, within the Healthcare sector 13 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 39, from total ROA ranking in the first quarter of 2026 at 42.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	152.04 %	186.75 %	214.52 %	73.96 %	61 %
Y / Y Net Income Change	-71 %	-24.39 %	1769.22 %	124.62 %	-
Net Income (TTM) in million	322	364	367	113	98
Return On Assets (TTM)	72.27 %	99.28 %	128.91 %	57.47 %	57.09 %
RIGL's Total Ranking	# 39	# 42	# 61	# 67	# 176
Total Assets (TTM) in million	521	505	514	243	207
Seq. Total Assets Change	3.26 %	-1.75 %	111.76 %	17.32 %	17.48 %
Seq. Net Income Change	99.79 %	-96.77 %	860.81 %	-53.2 %	420.82 %

RIGL's 5 Years Annual ROA >> Back to RIGL Management Effectiveness >> Compare RIGL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 6
Sector	# 14
Overall	# 47

Return On Assets Statistics
High	Average	Low
128.91 %	-28.54 %	-92.95 %
(Dec 31 2025)		(Mar 31 2018)

Financial Statements
Rigel Pharmaceuticals Inc's Assets	$ 521 million	RIGL's Balance sheet
Rigel Pharmaceuticals Inc's Income	$ 17 million	Quarterly RIGL's Income Statement
RIGL's Income by Division		See RIGL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	214.52 %	-68.43 %	285.15 %	-19.75 %	51.6 %
Total Assets in million	514	163	517	134	167
Y / Y Net Income Change	1999.08 %	-	-	-	-
Net Income in million	367	17	-25	-59	-18
Annual Return On Assets	71.46 %	10.71 %	-4.85 %	-43.62 %	-10.71 %

RIGL's 5 Years Annual ROA >> Back to RIGL Management Effectiveness >> Compare RIGL ROA to its Competitors

Comment on RIGL's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 71.46 % compared to prior year, due to annual net income growth of 1999.08 % to $367.02 million, while value of Rigel Pharmaceuticals Inc's overall assets grew just by 214.52 % to $513.59 million, compared to $513.59 a year before.

More Return On Assets Ratios
RIGL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RIGL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RIGL's Competitors
Subscribers only: Roa for Rigel Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for RIGL's Customers

You may also want to know
RIGL's Roi	RIGL's Inventory Turnover Ratio	RIGL's Growth Rates	RIGL's Dividend Comparisons
	RIGL's Profitability Ratios	RIGL's Asset Turnover Ratio	RIGL's Dividend Growth
RIGL's Roe	RIGL's Valuation Ratios	RIGL's Financial Strength Ratios	RIGL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %

Date modified: 2026-09-26T07:14:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.